The goal of this study is to investigate whether BIIB122 (study drug) may delay progression of PD. You may be eligible to participate if you are between 30 to 80 years of age and have been recently diagnosed with early-stage PD.

This study is to investigate if adding a medication called Lenrispodun to your current Parkinson's disease (PD) treatment can help make your symptoms better. You may be eligible to participate if you areexperiencing wearing OFF symptoms or dyskinesia and currently taking carbidopa/levodopa.

The FOG LIGHTS (Lessening Impairments in Gait with Hybrid Therapeutic Stimulation) Study is investigating the effectiveness of a new therapy for freezing of gait in people with Parkinsons who have an implanted deep brain stimulator. The purpose of the study is to determine whether or not CereGateTherapy can reduce freezing of gait in people with Parkinsons. CereGate therapy uses the Gevia™ DBS system that you already have, to create perceptible rhythmic sensations, or "cues", that may help to reduce your freezing of gait.

The purpose of this research study is to determine if DBS is a safe and effective therapy for severe freezing of gait in patients with Parkinson's Disease. Freezing of gait (FOG) is a particularly debilitating motor deficit seen in a subset of patients with Parkinson's Disease (PD).

For patients who have had DBS surgery with the Boston Scientific Study. The main goal is to characterize real-world clinical outcomes of DBS using a retrospective review of de-identified patient records. This study is data collection only.

Vercise™ DBS Registry: For patients considering Deep Brain Stimulation – Boston Scientific Corporation’s commercially approved Boston Scientific Vercise™ System for DBS. This study will evaluate the economic value and technical performance of the Vercise™ System.